NASDAQ
16.84USD
+0.49 (+3.00%)
We have scored 41 news catalysts on Beta Bionics, Inc. (BBNX) over the past 12 months. The biggest single-day move next to one of them came Oct 18, 2026, when BBNX closed −5.5%: “DAVA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Endava plc (DAVA) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026”. Coverage across the window leans negative (average ticker sentiment −0.77). Most of the impact sits in price momentum and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
757.6M
P/E
—
EPS
—
Beta
3.38
52W range
8.8-32.71
Day range
16.60–17.23
Open
16.60
Prev close
16.35
Volume
1.7M
Avg volume
1.2M
Dividend
0.00
IPO
2025-01-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Beta Bionics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BBNX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
